This trial is testing the safety of different doses of T cells that have been collected from the blood and modified to target HER2-negative breast cancer cells. The goal is to find a safe dose of these modified T cells that can be used to treat patients with metastatic breast cancer.
1 Primary · 0 Secondary · Reporting Duration: 2 years
Experimental Treatment
186 Total Participants · 1 Treatment Group
Primary Treatment: AP1903 · No Placebo Group · Phase 1
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 100.0% |
Met criteria | 100.0% |
3+ | 100.0% |